Trials / Completed
CompletedNCT01936805
ROsuvastatin LOading and Clinical Outcomes Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 299 (actual)
- Sponsor
- Yuksek Ihtisas Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel revascularization (TVR), or stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2013-09-06
- Last updated
- 2013-09-06
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01936805. Inclusion in this directory is not an endorsement.